Does this mean the higher dose is worse?

It means the higher dose was not better on the pain endpoints in this trial and was less well tolerated. Whether it is worse overall depends on which outcome is being optimised, in which population, and over what horizon - questions this trial was not designed to answer.

Could the two arms have differed at baseline?

In a randomised trial of this size, small chance imbalances are expected and are one of the reasons unpowered between-arm comparisons are unreliable. The published topline does not provide arm-level baseline pain, so the possibility cannot be excluded from the available sources.

How would you actually test for a direct effect on pain?

By dissociating weight change from drug exposure - for example, comparing groups matched on weight loss achieved by different means, or looking at whether pain improves before meaningful weight is lost. Trials of that design are harder to run and rarer, which is why the question stays open.

Is this specific to retatrutide?

No. The same logic applies to any intervention where a downstream outcome might be mediated by an intermediate one. The general principle - that a null difference between two active arms is weak evidence for any mechanism - is not about this compound at all.

GLP-1 & Incretin Science

More Weight Lost, No More Pain Relieved

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

TRIUMPH-4's higher dose arm lost 2.3 percentage points more body weight than the lower one but reported marginally less pain relief and fewer complete resolutions. That dissociation has several possible explanations, and the tempting one - a direct non-mechanical effect - is the weakest supported.

Key facts

Trial: TRIUMPH-4 (NCT05931367)
Weight, lower dose arm: -26.4% (efficacy estimand)
Weight, higher dose arm: -28.7% (efficacy estimand)
WOMAC pain, lower dose arm: -4.5 points (-75.8%)
WOMAC pain, higher dose arm: -4.4 points (-74.3%)
Complete resolution, lower dose: 14.1%
Complete resolution, higher dose: 12.0%
Discontinuation, lower vs higher: 12.2% vs 18.2%

The observation

Two active arms, one escalated to a higher dose than the other. The higher arm lost more weight: -28.7% against -26.4% on the efficacy estimand. On the pain endpoints it did not do better. WOMAC pain fell 4.4 points on the higher arm against 4.5 on the lower, and complete resolution of index knee pain was reported in 12.0% against 14.1%. If pain relief in knee osteoarthritis were a simple function of load removed from the joint, the arm that removed more load should have relieved more pain. It did not.

Reading one: the endpoint saturated

Mean baseline WOMAC pain was 6.0 on a 0-20 scale, and both arms removed about three-quarters of it. There is not much room left. An endpoint approaching its floor cannot register additional benefit, and the arm with more weight loss had nowhere to put it. This is the most parsimonious explanation and it is consistent with everything else in the trial, including the fact that both arms landed within 1.5 percentage points of each other in relative terms.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Reading two: it is noise

TRIUMPH-4 randomised 445 people three ways, which puts roughly 148 in each arm. The trial was designed to compare each active arm against placebo, not the two active arms against each other, and no such comparison would be adequately powered. A 0.1-point difference on a 20-point scale and a two-percentage-point difference in a binary responder rate are exactly the size of difference that appears and disappears between replicate trials. Treating them as findings is over-reading.

Reading three: the weight-pain relationship is non-linear

Joint loading falls with body mass, but the relationship between loading and pain need not be proportional across the whole range. If most of the symptomatic benefit accrues in the first fraction of weight lost - because that is what moves the joint out of the range where mechanical stress provokes symptoms - then additional weight loss beyond that point buys progressively less. On this reading the dissociation is real and mechanical, not evidence against a mechanical mechanism.

Reading four, and why it is the weakest

The tempting interpretation is that a component of the pain benefit is not mechanical at all - a direct effect on inflammation or nociception - and that this component plateaus while the weight effect does not. It is a coherent hypothesis and there is a plausible biological substrate for it. But it is not what this result shows. Absence of dose-tracking is a weak signal in both directions: it is equally consistent with saturation, with noise, and with non-linearity, all of which require no new mechanism. Inferring a direct effect from a null difference between two active arms is exactly the inference this class of data cannot support.

What the comparison does settle

One thing, clearly. The higher dose bought 2.3 percentage points more weight loss and six percentage points more discontinuation for adverse events - 18.2% against 12.2% - while measuring no better on either pain endpoint. In a trial whose co-primary endpoints are weight and pain, that is a straightforward argument about dose selection, and it is the kind of trade-off that decides which dose a sponsor takes forward. It is also invisible to anyone who reads only the largest number in the release.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does this mean the higher dose is worse?: It means the higher dose was not better on the pain endpoints in this trial and was less well tolerated. Whether it is worse overall depends on which outcome is being optimised, in which population, and over what horizon - questions this trial was not designed to answer.
Could the two arms have differed at baseline?: In a randomised trial of this size, small chance imbalances are expected and are one of the reasons unpowered between-arm comparisons are unreliable. The published topline does not provide arm-level baseline pain, so the possibility cannot be excluded from the available sources.
How would you actually test for a direct effect on pain?: By dissociating weight change from drug exposure - for example, comparing groups matched on weight loss achieved by different means, or looking at whether pain improves before meaningful weight is lost. Trials of that design are harder to run and rarer, which is why the question stays open.
Is this specific to retatrutide?: No. The same logic applies to any intervention where a downstream outcome might be mediated by an intermediate one. The general principle - that a null difference between two active arms is weak evidence for any mechanism - is not about this compound at all.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum